Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

February 03, 2026 08:05 ET | Source: Scienture Holdings, Inc.

SCIENTURE Provides Commercial Update on ARBLI™, the First FDA-Approved Ready-to-Use Oral Suspension of Losartan Potassium

Company highlights accelerating access and revenue growth for ARBLI™ and confirms REZENOPY™ launch timeline, addressing a combined US annual losartan and naloxone market size of close to $385 million ...